Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 4:6:278.
doi: 10.1186/1752-1947-6-278.

Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report

Mounia Lahbabi  1 , Meryem Ghissassi, Faouzi Belahcen, Sidi Adil Ibrahimi, Nouredine Aqodad
Affiliations

Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report

Mounia Lahbabi et al. J Med Case Rep. .

Abstract

Introduction: The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related to this combination therapy are mild and are well tolerated. However, peripheral neuropathy including demyelinating polyneuropathy related to PEG-interferon α2a (pegylated interferon alfa-2a) is extremely rare. In the literature, only one case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a has been published previously.

Case presentation: To the best of our knowledge we present only the second case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a, occurring in a 63-year-old Caucasian man. He developed tingling, numbness, and weakness of his upper and lower extremities with acute neurological deficits after five weeks of a combination therapy with PEG-interferon α2a and ribavirin for chronic hepatitis C virus infection. His clinical course, neurological findings, and his electromyogram results were all consistent with acute inflammatory demyelinating polyneuropathy. Our patient recovered completely after interferon was stopped and symptomatic treatment and a further electromyogram showed a disappearance of neuropathy. Four weeks later, PEG-interferon α2a was reintroduced with a gradually increasing dose without any reappearance of neurological symptoms allowing hepatitis C seroconversion.

Conclusions: Recognition of this rare yet possible presentation is important for early and accurate diagnosis and treatment. This case report also suggests that the reintroduction of PEGylated interferon in patients who had presented with acute inflammatory demyelinating polyneuropathy related to interferon α may be safe, but this must be confirmed by further studies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010;24:183–192. doi: 10.1016/j.bpg.2009.10.012. - DOI - PubMed
    1. Tellez-Zenteno JF, Negrete-Pulido O, Nunez M, Estanol-Vidal B, Garcia-Ramos G. Peripheral neuropathy during a second cycle of treatment with high doses of interferon-alpha in a patient with hepatitis C, and a review of the literature. Rev Neurol. 2002;35:644–646. - PubMed
    1. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve. 2000;23:433–435. doi: 10.1002/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O. - DOI - PubMed
    1. Stübgen JP. Interferon alpha and neuromuscular disorders. J Neuroimmunol. 2009;207:3–17. doi: 10.1016/j.jneuroim.2008.12.008. - DOI - PubMed
    1. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000;59:1251–1260. doi: 10.2165/00003495-200059060-00005. - DOI - PubMed

LinkOut - more resources